Three ways you can design better drug trials for schizophrenia therapeutics
To date, no effective drugs have been developed to address cognitive dysfunction in schizophrenia. Here we will highlight the three main methodological challenges which may be contributing to these high failure rates, and propose potential practical solutions to these problems.
CANTAB Research Grant funds investigation of chronic inflammation in depression
PhD Student Naoise Mac Giollabhui received a CANTAB Research Grant in 2018 for his project: ‘Chronic inflammation as a pathway to cognitive dysfunction in adolescents and young adults with a history of elevated depressive symptoms’. We caught up with Naoise to discuss how the grant will benefit his research.
Revolutionising the detection of cognitive impairment in multiple sclerosis with technology
Cognitive dysfunction is a leading cause of disability in multiple sclerosis (MS), yet practical restraints mean it often goes unassessed in routine clinical care. Promising new research, published in Frontiers in Neurology, suggests the Cambridge Neuropsychological Test Automated Battery (CANTAB) may offer a brief and sensitive technological solution.
Join us at SIRS 2018
Cambridge Cognition are attending the Schizophrenia International Research Society Conference (SIRS): 4th - 8th April 2018
Can acetylcholinesterase inhibitors and CNS stimulants tackle cognitive dysfunction in multiple scle
Cognitive dysfunction in multiple sclerosis (MS) presents a significant, unmet therapeutic need. Researchers at Cambridge Cognition and the University of Manchester investigated potential solutions to this problem with a systematic review and meta-analysis of pro-cognitive drug trials in MS.